SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Leblond V)
 

Search: WFRF:(Leblond V) > (2015-2019) > Treatment recommend...

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Leblond, V (author)
Kastritis, E (author)
Advani, R (author)
show more...
Ansell, SM (author)
Buske, C (author)
Castillo, JJ (author)
Garcia-Sanz, R (author)
Gertz, M (author)
Kimby, E (author)
Karolinska Institutet
Kyriakou, C (author)
Merlini, G (author)
Minnema, MC (author)
Morel, P (author)
Morra, E (author)
Rummel, M (author)
Wechalekar, A (author)
Patterson, CJ (author)
Treon, SP (author)
Dimopoulos, MA (author)
show less...
 (creator_code:org_t)
American Society of Hematology, 2016
2016
English.
In: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 128:10, s. 1321-1328
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström’s Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics. Chemoimmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durable responses and are still indicated in most patients. Approval of the BTK inhibitor ibrutinib in the United States and Europe represents a novel and effective treatment option for both treatment-naive and relapsing patients. Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising and may increase future treatment options. Active enrollment in clinical trials whenever possible was endorsed by the panel for most patients with WM.

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view